These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19623175)

  • 21. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [CEBPA gene mutation analysis in acute myeloid leukemia].
    Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
    Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
    Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.
    Marcolin R; Guolo F; Minetto P; Clavio M; Manconi L; Ballerini F; Carli A; Passannante M; Colombo N; Carminati E; Pugliese G; Tedone E; Contini P; Mangerini R; Kunkl A; Miglino M; Cagnetta A; Cea M; Gobbi M; Lemoli RM
    Leuk Res; 2019 Nov; 86():106223. PubMed ID: 31557597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.
    Zhao Y; Huang Y; Jiang L; Zhang Y; Liu F; Yan P; Yu G; Liu J; Jiang X
    Ann Hematol; 2024 Sep; 103(9):3595-3604. PubMed ID: 39020042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
    Ho PA; Alonzo TA; Gerbing RB; Pollard J; Stirewalt DL; Hurwitz C; Heerema NA; Hirsch B; Raimondi SC; Lange B; Franklin JL; Radich JP; Meshinchi S
    Blood; 2009 Jun; 113(26):6558-66. PubMed ID: 19304957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
    Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
    Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
    Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.
    van Vliet MH; Burgmer P; de Quartel L; Brand JP; de Best LC; Viëtor H; Löwenberg B; Valk PJ; van Beers EH
    Genet Test Mol Biomarkers; 2013 May; 17(5):395-400. PubMed ID: 23485358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [CD7 expression and its prognostic significance in acute myeloid leukemia patients with wild-type or mutant CEBPA].
    Zhu MY; Zhu Y; Chen RR; Zhu LX; Zhu JJ; Li XY; Zhou D; Yang XD; Zheng YL; Xie MX; Sun JN; Huang XB; Li L; Xie WZ; Ye XJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):100-105. PubMed ID: 32135624
    [No Abstract]   [Full Text] [Related]  

  • 35.
    Ng CWS; Kosmo B; Lee PL; Lee CK; Guo J; Chen Z; Chiu L; Lee HK; Ho S; Zhou J; Lin M; Tan KML; Ban KHK; Tan TW; Chng WJ; Yan B
    J Clin Pathol; 2018 Jun; 71(6):522-531. PubMed ID: 29180507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
    Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
    Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.
    Yuan J; He R; Alkhateeb HB
    Curr Hematol Malig Rep; 2023 Oct; 18(5):121-129. PubMed ID: 37261703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
    Pabst T; Mueller BU
    Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
    Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
    J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.